Cortical neurons in Dementia with Lewy Bodies (DLB) represent a critical population of neurons that undergo significant degeneration and pathology in this second most common neurodegenerative dementia. Unlike Alzheimer's disease, where tau and amyloid pathology dominate, DLB is characterized by the widespread distribution of Lewy bodies (alpha-synuclein inclusions) throughout the cortical layers, leading to distinctive clinical features including visual hallucinations, fluctuating cognition, and parkinsonism.
Dementia with Lewy bodies (DLB) is characterized by Lewy body pathology throughout the cortex, causing fluctuations, visual hallucinations, and parkinsonism. Cortical involvement is a hallmark feature that distinguishes DLB from Parkinson's disease dementia and contributes to the unique cognitive profile observed in patients.
- Lewy body pathology: Alpha-synuclein positive inclusions throughout cortical layers
- Sparing of pyramidal neurons: Relative preservation compared to other neurodegenerative conditions
- Layer-specific vulnerability: Layer II and V neurons show greatest pathology
- Synaptic loss: Correlates strongly with cognitive decline
¶ Lewy Body Distribution
Cortical neurons show:
- Lewy bodies (alpha-synuclein)
- Sparse amyloid plaques
- Less tau pathology than AD
- Fluctuating cognition
| Layer |
Neuron Type |
Vulnerability |
Pathology |
| II |
Stellate cells |
High |
Early Lewy bodies |
| III |
Pyramidal cells |
Moderate |
Moderate pathology |
| V |
Pyramidal cells |
High |
Late-stage involvement |
| VI |
Multipolar cells |
Moderate |
Variable pathology |
- Acetylcholine: 50-70% reduction in cortical cholinergic innervation
- Dopamine: Moderate loss in mesocortical projections
- Serotonin: Reduced in dorsal raphe projections
- GABA: Variable loss depending on region
¶ Attention and Executive Function
- Fluctuating attention: Hour-to-hour variation in alertness
- Executive dysfunction: Impaired planning and problem-solving
- Working memory deficits: Difficulty holding information
- Visual processing deficits: Impaired object recognition
- Spatial orientation: Navigation difficulties
- Constructional apraxia: Inability to copy figures
- Visual hallucinations: Early and prominent feature (up to 80% of patients)
- Depression: Common in early stages
- Delusions: Often paranoid or misidentification type
- Apathy: Reduced motivation and initiative
- Parkinsonism: Bradykinesia, rigidity, tremor
- Gait dysfunction: Falls due to postural instability
- Motor fluctuations: Variable response to levodopa
- Native α-synuclein: Normally soluble neuronal protein
- Oligomer formation: Toxic intermediate species
- Fibril accumulation: Lewy body formation
- Spread: Prion-like propagation between neurons
- Synaptic dysfunction: Impaired neurotransmitter release
- Mitochondrial damage: Complex I inhibition
- Oxidative stress: ROS accumulation
- Neuroinflammation: Microglial activation
- Amyloid co-pathology: Present in 50-70% of cases
- Tau pathology: Less severe than in AD
- vascular contributions: Small vessel disease common
- Donepezil: First-line for cognitive symptoms
- Rivastigmine: May improve behavioral symptoms
- Galantamine: Dual action mechanism
- Levodopa: May improve motor symptoms
- Dopamine agonists: Variable response
- MAO-B inhibitors: May help motor function
- Immunotherapy: Active and passive vaccination trials
- Small molecule inhibitors: Preventing aggregation
- Gene therapy: AAV-mediated protein expression
- Neurotrophic factors: BDNF and GDNF delivery
- Antioxidants: Mitochondrial protection
- Anti-inflammatory agents: Microglial modulation
- CSF alpha-synuclein: Phosphorylated and total species
- PET imaging: Tau and amyloid ligands
- EEG changes: Slowing correlates with severity
- Synuclein aggregation inhibitors: In clinical trials
- Cell replacement therapy: Stem cell approaches
- Gene silencing: ASO and siRNA strategies
The study of Cortical Neurons in Dementia with Lewy Bodies has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
The identification of alpha-synuclein as the major component of Lewy bodies in 1997 revolutionized our understanding of DLB pathogenesis. Subsequent research has demonstrated the prion-like properties of alpha-synuclein and its ability to spread throughout the nervous system, explaining the progressive cortical involvement observed in DLB patients.
- DLB
- Parkinson's Diseaseparkin)
- α-Synuclein
- /mechanisms/alpha-synuclein-pathology
- α-Syn Biomarkers
- /cell-types/cholinergic-neurons-dementia-lewy-bodies
- /cell-types/nigral-dopaminergic-neurons-dementia-lewy-bodies
- /cell-types/locus-coeruleus-neurons-dementia-lewy-bodies
- /therapeutics/dementia-lewy-bodies-treatment
- DLB Biomarkers